文献速递妇科

在新诊断晚期卵巢癌患者中,根据临床风险分析奥拉帕利联合贝伐珠单抗维持治疗的疗效:III期PAOLA-1/ENGOT-ov25试验

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
PubMed 文献 · Gynecol Oncol · 2021-12-22

PAOLA-1/ENGOT-ov25试验事后探索性分析按临床风险(较高危:III期初次手术有残留病灶或新辅助化疗、IV期;较低危:III期初次手术无残留病灶)和生物标志物状态评估PFS。中位随访22.9个月,较高危和较低危患者中奥拉帕利联合贝伐珠单抗均优于安慰剂联合贝伐珠单抗,HRD阳性亚组获益显著。

要点

  • 较高危患者中奥拉帕利联合贝伐珠单抗较安慰剂联合贝伐珠单抗显著改善PFS(HR 0.60)。
  • 较低危患者中奥拉帕利联合贝伐珠单抗较安慰剂联合贝伐珠单抗显著改善PFS(HR 0.46)。
  • HRD阳性较低危患者24个月PFS率奥拉帕利联合贝伐珠单抗组90% vs 安慰剂联合贝伐珠单抗组43%。

核心结论

  • 在PAOLA-1中,奥拉帕利联合贝伐珠单抗维持治疗在HRD阳性患者中提供显著PFS获益,较高危组疾病进展或死亡风险较安慰剂联合贝伐珠单抗降低61%,较低危组降低85%。

研究设计与样本

  • 随机、双盲III期PAOLA-1/ENGOT-ov25试验(NCT02477644)的事后探索性分析,共806例随机患者。
  • 患者接受奥拉帕利300 mg每日两次(最多24个月)联合贝伐珠单抗15 mg/kg每3周(总共最多15个月),或安慰剂联合贝伐珠单抗。
  • 按临床风险分类:较高危(III期初次手术有残留病灶或新辅助化疗;IV期)占74%,较低危(III期初次手术无残留病灶)占26%。

主要发现

  • 中位随访22.9个月,较高危患者中奥拉帕利联合贝伐珠单抗 vs 安慰剂联合贝伐珠单抗的PFS HR为0.60(95%CI 0.49-0.74)。
  • 较低危患者中奥拉帕利联合贝伐珠单抗 vs 安慰剂联合贝伐珠单抗的PFS HR为0.46(95%CI 0.30-0.72)。
  • HRD阳性较高危亚组中奥拉帕利联合贝伐珠单抗 vs 安慰剂联合贝伐珠单抗的PFS HR为0.39(95%CI 0.28-0.54)。
  • HRD阳性较低危亚组中奥拉帕利联合贝伐珠单抗 vs 安慰剂联合贝伐珠单抗的PFS HR为0.15(95%CI 0.07-0.30)。
  • HRD阳性较低危患者24个月PFS率奥拉帕利联合贝伐珠单抗组90% vs 安慰剂联合贝伐珠单抗组43%(Kaplan-Meier估计)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Adding maintenance olaparib to bevacizumab provided a significant progression-free survival (PFS) benefit in patients with newly diagnosed, advanced ovarian cancer in the randomized, double-blind PAOLA-1/ENGOT-ov25 trial (NCT02477644). We analyzed PFS by clinical risk and biomarker status. METHODS: Patients received olaparib 300 mg twice daily for up to 24 months plus bevacizumab 15 mg/kg every 3 weeks for up to 15 months in total, or placebo plus bevacizumab. This post hoc exploratory analysis evaluated PFS in patients classified as higher risk (stage III with upfront surgery and residual disease or neoadjuvant chemotherapy; stage IV) or lower risk (stage III with upfront surgery and no residual disease), and by biomarker status. RESULTS: Of 806 randomized patients, 74% were higher risk and 26% were lower risk. After a median 22.9 months of follow-up, PFS favored olaparib plus bevacizumab versus placebo plus bevacizumab in higher-risk patients (hazard ratio [HR] 0.60; 95% confidence interval [CI] 0.49-0.74) and lower-risk patients (0.46; 0.30-0.72). Olaparib plus bevacizumab provided a substantial PFS benefit versus bevacizumab alone in the homologous recombination deficiency (HRD)-positive subgroup (higher risk: HR 0.39; 95% CI 0.28-0.54 and lower risk: 0.15; 0.07-0.30), with 24-month PFS rates in lower-risk patients of 90% versus 43%, respectively (Kaplan-Meier estimates). CONCLUSIONS: In PAOLA-1, maintenance olaparib plus bevacizumab provided a substantial PFS benefit in HRD-positive patients with a reduction of risk of progression or death of 61% in the higher-risk group and of 85% in the lower-risk group compared with bevacizumab alone.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Harter P, Mouret-Reynier MA, Pignata S, et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Gynecol Oncol. 2021. PMID: 34952708. doi:10.1016/j.ygyno.2021.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。